A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): Study protocol for a randomized controlled trial

Trials

Volumn 14, Issue 1, 2013, Pages

  Hull, Mark A ^a   Sandell, Anna C ^b   Montgomery, Alan A ^b   Logan, Richard F A ^c   Clifford, Gayle M ^d   Rees, Colin J ^d   Loadman, Paul M ^e   Whitham, Diane ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d CITY HOSPITALS SUNDERLAND NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Aspirin; Colorectal adenoma; Colorectal cancer; Eicosapentaenoic acid; Omega 3 polyunsaturated fatty acid

Indexed keywords

ACETYLSALICYLIC ACID; ICOSAPENTAENOIC ACID; PLACEBO; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; BLEEDING; CANCER PREVENTION; CANCER SCREENING; COLONOSCOPY; COLORECTAL ADENOMA; DRUG SAFETY; ERYTHROCYTE; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM MUCOSA; ADENOMA; AGED; CLINICAL PROTOCOL; COLORECTAL NEOPLASMS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NATIONAL HEALTH SERVICE; PATHOLOGY; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

ADENOMA; AGED; ANTICARCINOGENIC AGENTS; ASPIRIN; CLINICAL PROTOCOLS; COLONOSCOPY; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; ENGLAND; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SAMPLE SIZE; STATE MEDICINE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84880946220     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-237     Document Type: Article

References (29)

1. Boursi B, Arber N. Current and future clinical strategies in colon cancer prevention and the emerging role of chemoprevention. Curr Pharm Des 2007, 13:2274-2282. 10.2174/138161207781368783, 17692000.
2. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JMA, Parkin DM, Wardle J, Duffy SW, Cuzick J, UK Flexible Sigmoidoscopy Trial Investigators Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010, 375:1624-1633. 10.1016/S0140-6736(10)60551-X, 20430429, UK Flexible Sigmoidoscopy Trial Investigators.
3. Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012, 366:687-696. 10.1056/NEJMoa1100370, 3322371, 22356322.
4. Brenner H, Chang-Claude J, Seiler CM, Hoffmeister M. Interval cancers after negative colonoscopy: population-based case-control study. Gut 2012, 61:1576-1582. 10.1136/gutjnl-2011-301531, 22200840.
5. Hassan C, Rex DK, Cooper GS, Zullo A, Launois R, Benamouzig R. Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis. Gut 2012, 61:1172-1179. 10.1136/gutjnl-2011-300206, 21997545.
6. Hull MA. Nutritional agents with anti-inflammatory properties in chemoprevention of colorectal neoplasia. Recent Results Cancer Res 2012, 191:143-156.
7. Chan AT, Arber N, Burn J, Chia W-K, Elwood P, Hull MA, Logan RF, Rothwell PM, Schrör K, Baron JA. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res 2011, 5:164-178.
8. Zhou P, Cheng SW, Yang R, Wang B, Liu J. Combination chemoprevention: future direction of colorectal cancer prevention. Eur J Cancer Prev 2012, 21:231-240. 10.1097/CEJ.0b013e32834dbbfd, 22456425.
9. Lavie C, Milani R, Mehra M, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009, 54:585-594. 10.1016/j.jacc.2009.02.084, 19660687.
10. Hull MA. Omega-3 polyunsaturated fatty acids. Best Pract Res Clin Gastroenterol 2011, 25:547-554. 10.1016/j.bpg.2011.08.001, 22122770.
11. Cockbain AJ, Toogood GJ, Hull MA. Omega-3 polyunsaturated fatty acids for the prevention and treatment of colorectal cancer. Gut 2012, 61:135-149. 10.1136/gut.2010.233718, 21490374.
12. Murff HJ, Shrubsole MJ, Cai Q, Smalley WE, Dai Q, Milne GL, Ness RM, Zheng W. Dietary intake of PUFAs and colorectal polyp risk. Am J Clin Nutr 2012, 95:703-712. 10.3945/ajcn.111.024000, 3278245, 22277551.
13. Lawson L, Hughes B. Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters. Biochem Biophys Res Comm 1988, 152:328-335. 10.1016/S0006-291X(88)80718-6, 3358766.
14. Fini L, Piazzi G, Ceccarelli C, Daoud Y, Belluzzi A, Munarini A, Graziani G, Fogliano V, Selgrad M, Garcia M, Gasbarrini A, Genta RM, Boland CR, Ricciardiello L. Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in ApcMin/+ Mice. Clin Cancer Res 2010, 16:5703-5711. 10.1158/1078-0432.CCR-10-1990, 21030497.
15. West NJ, Clark SK, Phillips RKS, Hutchinson JM, Leicester RJ, Belluzzi A, Hull MA. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 2010, 59:918-925. 10.1136/gut.2009.200642, 20348368.
16. Steinbach G, Lynch P, Phillips R, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946-1952. 10.1056/NEJM200006293422603, 10874062.
17. Arber N, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 2008, 134:1224-1237. 10.1053/j.gastro.2008.02.012, 18395100.
18. Smith W. Cyclooxygenases, peroxide tone and the allure of fish oil. Curr Opin Cell Biol 2005, 17:174-182. 10.1016/j.ceb.2005.02.005, 15780594.
19. Greene ER, Huang S, Serhan CN, Panigrahy D. Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat 2011, 96:27-36. 10.1016/j.prostaglandins.2011.08.004, 21864702.
20. Larson MK, Ashmore JH, Harris KA, Vogelaar JL, Pottala JV, Sprehe M, Harris WS. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost 2008, 100:634-641.
21. Block RC, Kakinami L, Jonovich M, Antonetti I, Lawrence P, Meedhu N, Calderon Artero P, Mousa SA, Brenna JT, Georas S. The combination of EPA + DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy volunteers. Prostaglandins Leukot Essent Fatty Acids 2012, 87:143-151. 10.1016/j.plefa.2012.08.007, 23017325.
22. Cole B, Logan R, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. JNCI 2009, 101:256-266. 10.1093/jnci/djn485, 19211452.
23. Cairns SR, Scholefield JH, Steele RJC, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010, 59:666-690. 10.1136/gut.2009.179804, 20427401.
24. Bensen S, Mott L, Dain B, Rothstein R, Baron J. The colonoscopic miss rate and true one-year recurrence of colorectal neoplastic polyps. Am J Gastroenterol 1999, 94:194-199. 10.1111/j.1572-0241.1999.00796.x, 9934755.
25. NHS Bowel Cancer Screening Programme Quality Assurance Guidelines for Colonoscopy 2011, UK: NHS BCSP Publication, 6, NHS Bowel Cancer Screening Programme.
26. Brouwer I, Zock P, Wever E, Hauer RN, Camm AJ, Böcker D, Otto-Terlouw P, Katan MB, Schouten EG. Rationale and design of a randomised controlled trial on supplemental intake of n-3 fatty acids and incidence of cardiac arrhythmia: SOFA. Eur J Clin Nutr 2003, 57:1323-1330. 10.1038/sj.ejcn.1601695, 14506496.
27. Farmer A, Montori V, Dinneen D, Clar C. Fish oil in people with type 2 diabetes mellitus (Cochrane Review). Cochrane Database Syst Rev 2001, 3. CD003205.
28. Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002, 76:1007-1015.
29. McAlister F, Straus S, Sackett D, Altman DG. Analysis and reporting of factorial trials. JAMA 2003, 289:2545-2553. 10.1001/jama.289.19.2545, 12759326.